| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from IINN graph: em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring.… |
| ABT |
Abbott Laboratories |
72%
|
em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and the disposable unit consist of both … |
| BDX |
Becton, Dickinson and Company |
72%
|
Reciprocal relationship from BDX graph: Reciprocal relationship from IINN graph: em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring.… |
| BDX |
Becton, Dickinson and Company |
72%
|
em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and the disposable unit consist of both … |
| BSX |
Boston Scientific Corporation |
72%
|
Reciprocal relationship from BSX graph: Reciprocal relationship from IINN graph: Reciprocal relationship from BSX graph: Reciprocal relationship from IINN graph: em) as well as a disposable unit to b… |
| BSX |
Boston Scientific Corporation |
72%
|
em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and the disposable unit consist of both … |
| FSNUY |
Fresenius SE & Co. KGaA |
72%
|
Reciprocal relationship from FSNUY graph: Reciprocal relationship from IINN graph: Reciprocal relationship from FSNUY graph: Reciprocal relationship from IINN graph: em) as well as a disposable unit … |
| FSNUY |
Fresenius SE & Co. KGaA |
72%
|
em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and the disposable unit consist of both … |
| GTLS |
Chart Industries, Inc. |
72%
|
Reciprocal relationship from GTLS graph: Reciprocal relationship from IINN graph: Reciprocal relationship from GTLS graph: Reciprocal relationship from IINN graph: em) as well as a disposable unit to… |
| GTLS |
Chart Industries, Inc. |
72%
|
em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and the disposable unit consist of both … |
| JNJ |
Johnson & Johnson |
72%
|
em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and the disposable unit consist of both … |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from IINN graph: em) as well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring.… |
| NNDM |
Nano Dimension Ltd. |
72%
|
esults of operations for the years ended December 31, 2025, and December 31, 2024: Year Ended December 31, U.S. dollars in thousands 2025 2024 Increase/Decrease Revenues 289 - 289 Cost of revenues 28… |
| NNDM |
Nano Dimension Ltd. |
72%
|
Reciprocal relationship from NNDM graph: Reciprocal relationship from IINN graph: esults of operations for the years ended December 31, 2025, and December 31, 2024: Year Ended December 31, U.S. dolla… |
| CLEARX-MEDICAL-LTD |
CLEARX-MEDICAL-LTD |
62%
|
e risks to study subjects outweigh the anticipated benefits. 57 Table of Contents Post-market Regulation After a device is cleared or approved for marketing, numerous and extensive regulatory require… |
| CME |
CME Group Inc. |
62%
|
Reciprocal relationship from CME graph: Reciprocal relationship from IINN graph: Reciprocal relationship from CME graph: Reciprocal relationship from IINN graph: Reciprocal relationship from CME grap… |
| GLO-MED-NETWORKS-INC |
GLO-MED-NETWORKS-INC |
62%
|
t we will incur continued losses for the foreseeable future; ● We could fail to maintain the listing of our securities on Nasdaq, which could seriously harm the liquidity of our shares and our abilit… |
| INSENSE-MEDICAL-LTD |
INSENSE-MEDICAL-LTD |
62%
|
e risks to study subjects outweigh the anticipated benefits. 57 Table of Contents Post-market Regulation After a device is cleared or approved for marketing, numerous and extensive regulatory require… |
